Incannex Healthcare Halted, News Pending
ORLANDO, Fla. - Nutriband Inc. (NASDAQ:NTRB), a developer of prescription transdermal pharmaceutical products with a market capitalization of $85.7 million, has announced the issuance of a new patent by the United States Patent and Trademark Office (USPTO) for its AVERSA™ abuse deterrent technology. The patent, numbered 12,318,492 and issued on June 3, 2025, is titled "Abuse and Misuse Deterrent Transdermal Systems." According to InvestingPro data, the company maintains strong liquidity with a current ratio of 3.71, indicating solid short-term financial stability.
The AVERSA™ technology is designed to be incorporated into transdermal patches, aiming to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. This recent patent expands Nutriband’s intellectual property rights in the U.S. and complements its existing portfolio with patents issued in 46 countries, including major markets such as Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia. The company has demonstrated promising growth, with revenue increasing by 18.92% over the last twelve months.
Nutriband’s leading product in development is Aversa™ Fentanyl, a fentanyl transdermal system that incorporates the AVERSA™ technology. It has the potential to become the first abuse deterrent pain patch on the market, with projected peak annual U.S. sales estimated between $80 million and $200 million, according to a 2022 market analysis report by Health Advances. The stock has shown strong momentum, gaining over 86% in the past six months, with analysts setting a target price of $13. Get more detailed analysis and 10+ additional ProTips with InvestingPro.
The AVERSA™ abuse-deterrent transdermal technology integrates aversive agents into patches to enhance the safety profile of medications prone to abuse, such as fentanyl, while ensuring their availability for patients in need. Nutriband’s focus on developing transdermal pharmaceutical products is part of a broader strategy to address issues of drug misuse and provide safer alternatives for medication delivery.
This press release statement serves as the basis for the reported facts. Nutriband has cautioned that certain statements made in the press release are forward-looking and involve risks and uncertainties, including the development and regulatory approval of its products. The company has emphasized its commitment to advancing the AVERSA™ technology but acknowledges the challenges associated with bringing new pharmaceutical products to market.
In other recent news, Nutriband Inc. has been actively advancing its pharmaceutical endeavors with several key developments. The company has outlined its progress in commercializing its AVERSA Fentanyl, an abuse-deterrent opioid patch, with projected peak annual sales between $80 million and $200 million. Nutriband’s subsidiary, Pocono Pharma, is experiencing strong revenue growth in its contract manufacturing services, notably with kinesiology tape. Additionally, Nutriband has secured a patent in Macao for its AVERSA technology, expanding its intellectual property portfolio to 46 countries. The company continues its exclusive partnership with Kindeva Drug Delivery to develop AVERSA Fentanyl, aiming to create the first abuse-deterrent opioid patch on the market. In a strategic move to boost brand visibility, Nutriband announced an Associate Partnership with Charlotte FC, aligning with its local manufacturing efforts. The company’s future plans include initiating a pivotal Human Abuse Liability clinical trial and filing an Investigational New Drug application with the FDA. Nutriband is also exploring international partnerships and licensing opportunities for its AVERSA technology. These recent developments highlight Nutriband’s ongoing efforts to address pain management needs while enhancing shareholder value.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.